Dr. Andrew John Hutchinson, DO Surgery Medicare: Accepting Medicare Assignments Practice Location: 701 Jefferson St, Whiteville, NC 28472 Phone: 910-640-2051 Fax: 910-640-2059 |
Dr. Hugh Rollins Daniel, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 508 Jefferson St, Whiteville, NC 28472 Phone: 910-640-2480 Fax: 910-640-2487 |
Dr. David Lawrence Greco, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 220 Jefferson St, Whiteville, NC 28472 Phone: 910-642-3214 Fax: 910-642-2085 |
Dr. Ronald Martin Walters, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 220 Jefferson St, Whiteville, NC 28472 Phone: 910-642-3214 Fax: 910-642-2085 |
News Archive
Diabetes is characterized by elevated levels of sugar or glucose (hyperglycemia) in the blood. This occurs due to the lack of the hormone insulin in type 1 diabetes, and to reduced insulin levels in combination with insulin resistance in type 2 diabetes.
In the era of launching Kickstarter campaigns to pay for just about anything, Carnegie Mellon University ethicists warn that the trend of patients funding their own clinical trials may do more harm than good.
Health Care Compliance Strategies, Inc. (HCCS), the leading provider of online healthcare compliance and competency training, today announced the release of a new online compliance training course designed specifically for nursing facilities including nursing homes, skilled nursing facilities and other long term care providers.
Collecting sexual orientation and gender identity, or "SO/GI," data has valuable public health benefits and potential clinical benefits for an individual patient, but medical providers must continue to collect information about patient experiences and behaviors, where clinically appropriate, and avoid making assumptions based on SO/GI data alone, according to a study from researchers at the Perelman School of Medicine at the University of Pennsylvania published today in the Journal of General Internal Medicine.
Zalicus Inc., a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases, announced that it is has successfully completed a Phase 1 single ascending dose (SAD) clinical study with Z944, its novel, oral, T-type calcium channel blocker.
› Verified 6 days ago